HEAD AND NECK CANCER

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in people with advanced solid tumors like breast, kidney, ovarian, head and neck, colorectal, lung cancer, or melanoma. The goal was to check safety and see if tumors shrank. The st…

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if niraparib could shrink tumors or slow their growth. The study was stopped ear…

This study tested a combination of two drugs, niraparib and dostarlimab, in adults with advanced solid tumors that either had DNA repair problems or were sensitive to platinum chemotherapy. The goal was to see how many patients' tumors shrank or disappeared. The trial was stopped…

This study tested a new drug called xevinapant combined with standard chemotherapy (carboplatin and paclitaxel) and radiation for people with advanced head and neck cancer who cannot take the usual chemo drug cisplatin. The main goal was to find the safest dose of xevinapant to u…

This study looked at whether a structured smoking cessation program, started four weeks before surgery, could reduce complications in smokers undergoing intermediate to high-risk operations. The trial planned to enroll 251 patients but was terminated early. The goal was to compar…

This study tested whether a special oral care routine, including dental cleaning and mouth treatments, could reduce severe mouth sores in people receiving radiation for head and neck cancer. About 60 participants were assigned to either the special care or standard brushing. The …

This study tested whether adding the drug xevinapant to standard radiation therapy could help prevent head and neck cancer from coming back after surgery. It included 166 people whose cancer was at high risk of relapse and who could not take the usual chemotherapy drug cisplatin.…

This early-phase study tested a new medicine called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, skin, head and neck, or colorectal cancer. The goal was to check safety and how the body handles the dr…

This early-phase study tested whether adding an experimental drug called xevinapant to standard weekly chemotherapy and radiation was safe and tolerable for people with advanced head and neck cancer. It involved 18 participants with cancer that could not be removed by surgery. Th…

This study aimed to see if a mental health app could help head and neck cancer survivors with depression. Participants would use the app for 6 weeks and fill out surveys. However, the study was stopped early and only enrolled 1 person, so no meaningful results were obtained.

This study aimed to find the best way to monitor patients after they finish treatment for head and neck cancer. Researchers compared a personalized follow-up schedule, based on each patient's needs, to the usual one-size-fits-all approach. The goal was to see if a tailored plan c…